Aprepitant Capsules and Osimertinib Mesylate
Determining the interaction of Aprepitant Capsules and Osimertinib Mesylate and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Aprepitant may increase the blood levels of osimertinib. In some cases, this may increase the risk and/or severity of side effects such as nausea, diarrhea, mouth sores, heart muscle problems (e.G., heart failure), and irregular heart rhythm. Contact your doctor if your condition changes or you experience increased side effects. You may need a dose adjustment or more frequent monitoring to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of osimertinib, which has been shown in vitro to be primarily metabolized by the isoenzyme. However, no pharmacokinetic data are available from drug interaction studies. Because osimertinib is associated with concentration-dependent prolongation of the QT interval, increased levels may potentiate the risk of ventricular arrhythmias such as torsade de pointes and sudden death.
MANAGEMENT: Caution is advised when osimertinib is prescribed with CYP450 3A4 inhibitors. Patients should be monitored for adverse effects such as diarrhea, QT prolongation, torsade de pointes arrhythmia, and cardiomyopathy (e.g., cardiac failure, pulmonary edema, ejection fraction decreases), and the osimertinib dosage adjusted accordingly or treatment discontinued as necessary.
- "Product Information. Tagrisso (osimertinib)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.
Generic Name: aprepitant
Brand name: Cinvanti, Emend, Emend 3-Day, Emend 2-Day
Synonyms: Aprepitant
Generic Name: osimertinib
Brand name: Tagrisso
Synonyms: Osimertinib
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Aprepitant Capsules-Osmitrol
- Aprepitant Capsules-Osmolex ER
- Aprepitant Capsules-OsmoPrep
- Aprepitant Capsules-OsmoPrep Oral
- Aprepitant Capsules-Ospemifene
- Aprepitant Capsules-Osphena
- Osimertinib Mesylate-Aprepitant Injection
- Osimertinib Mesylate-Aprepitant Intravenous
- Osimertinib Mesylate-Aprepitant Oral Suspension
- Osimertinib Mesylate-Aprepitant/Fosaprepitant Dimeglumine
- Osimertinib Mesylate-Apresazide
- Osimertinib Mesylate-Apresoline